Abstract Hypoxia inducible factor (HIF)-1α is the central transcriptional factor for the regulation of oxygen-associated genes in response to hypoxia. Erythropoietin (EPO), a hematopoietic growth factor, increases oxygen availability during hypoxia/ischemia and is associated with neuroprotection following hypoxia-ischemia in laboratory models of stroke. However, EPO has failed to translate in a clinical setting. Thus, it is critical to elucidate the key players in EPOinduced neuroprotection. Our preliminary studies have shown that EPO, as a downstream gene of HIF, inhibits HIF-1α in a dose-dependent manner in an in vitro model of hypoxiaischemia. This study is designed to elucidate the primary mediator of EPO-induced HIF-1α inhibition and subsequent cell survival/neuroprotection. Oxygen and glucose deprivation (OGD) of nerve growth factor-differentiated rat pheochromocytoma (PC-12) cells were used to model hypoxiaischemia in an in vitro environment. The profile of HIF-1α, HIF-2α and prolyl hydroxylase domain 2 (PHD-2) expression; HIF-1α and prolyl hydroxylase (PHD-2) mRNA levels; matrix metalloproteinase (MMP)-9; and cell death was evaluated in the presence and absence of either EPO or PHD-2 inhibitor during OGD. Our findings showed that EPO treatment resulted in an increase in PHD-2 transcription and translation, inhibition of HIF-1α expression, reactive oxygen species formation, and MMP-9 activity, resulting in increased cell survival after OGD. We also observed that EPO-induced cell survival/neuroprotection was reversed by siRNA silencing of PHD-2. This led to the conclusion that PHD-2 is a key mediator of EPO-induced HIF-1α inhibition and subsequent neuroprotection in an in vitro model of hypoxia-ischemia.
Introduction
Stroke continues to be among the leading causes of mortality and morbidity; ischemic stroke accounts for approximately 75 % of all incidents (ASA, AHA). Despite extensive stroke research, there are still very limited therapeutic options available.
Hypoxia inducible factor (HIF)-1α and HIF-2α are innate modulators of oxygen homeostasis in most aerobes [42] . However, the specific HIF that is associated with erythropoietin (EPO), neurons, and neuroprotection is still a topic of frequent debate [41] . Cerebral ischemia promotes an accumulation of HIF-1α in neurons. During conditions of hypoxia, HIF-1α initiates the transcription of vascular endothelial growth factor (VEGF) [30] , EPO [31] , glucose transporter (GLU-1), glycolytic enzymes [21] , and several prosurvival genes. However, HIF-1α is also associated in promoting the transcription of proapoptotic genes such as matrix metalloproteinase (MMP)-9 [9] , Bcl2/adenovirus EIB 19kD-interacting protein 3 [5] , Nix [37] , p53, and the caspases [28] . Under normoxic condition, HIF-1α is continuously synthesized and degraded in less than 5 min through the ubiquitin-proteasome pathway [17, 22, 33] . HIF-1α first undergoes hydroxylation by prolyl hydroxylase domain (PHD)-2, which allows it to interact with the von Hippel-Lindau (VHL) tumor suppressor gene [19, 20, 25] . This interaction allows for the poly ubiquitination and proteasome-dependent degradation of HIF-1α.
PHDs are a family of three hydroxylase (PHD1-3) that are responsible for the hydroxylation of HIF in mammals. Recent studies have shown that PHD-2 activity is critical for HIF-1α degradation under normoxic conditions [2, 4] . PHD-2 has a strikingly low O 2 affinity, which is ideal for oxygen sensing [13, 16] . The absence of oxygen or reactive oxygen species (ROS) promotes the destabilization of PHD-2 [7, 13, 14, 21] . HIF degradation pathways require either hydroxylation or acetylation, which is PHD-2-and oxygen-dependent [7, 13, 14, 21] .
HIF-1α target gene, EPO, has been shown to modulate other target genes of HIF-1α such as MMPs, VEGF, cyclooxygenase, nitric oxide synthase, and p53 [40] . Preclinical studies yielded promising results for the use of EPO in stroke therapy [39] . However, the effects of EPO on HIF-1α or its primary regulator PHD-2 have not been demonstrated. EPO was shown to stabilize mitochondrial membrane potential and decrease ROS in Abeta (25-35)-induced neuronal toxicity in pheochromocytoma (PC)-12 cells, which are upregulated antiapoptotic and downregulated proapoptotic proteins [28] . Although clinical trials using EPO in stroke therapy failed [12] , it is still imperative to identify the key mediators of EPOinduced neuroprotection. This information will allow for a better prediction of the side effects and ultimately improve clinical translation. We hypothesized that EPO treatment will increase PHD-2 during hypoxia, attenuating ROS and HIF-1α accumulation. We have explored this hypothesis using the oxygen and glucose deprivation (OGD) model with nerve growth factor (NGF)-differentiated PC-12 cells. The protein expression of HIF-1α, HIF-2α, PHD-2, and VHL, as well as ROS formation in the presence and absence of EPO treatment during OGD were assessed. We then investigated if pharmacological inhibition of EPO receptor or siRNA silencing of PHD-2 increases ROS formation and negates EPO-induced neuroprotection during OGD. Neuroprotection was assessed by the percentage of cell death following OGD.
Material
The cell line (Rat pheochromocytoma cells, PC-12 cells) and serum supplements were obtained from ATCC (Manassas, VA.). Human recombinant EPO (Procrit ©) was from Loma Linda University, Hospital Pharmacy (Loma Linda, CA). EPO receptor protein chimera (EPOR-Fc chimera) was purchased from Abcam (Cambridge, MA). NGF was obtained from Alomone Laboratories Ltd. (Jerusalem, Israel). Rat primary antibodies for HIF-1α and HIF-2α were from ABD Serortec (Raleigh, NC). HIF-PHD-2 antibody, β-actin, and all secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Poly-L-lysine-coated culture dishes were from BD Biosciences (San Diego, CA). Gelatin gel, TRIZOL reagent, siRNA, and primers were from Invitrogen (Carlsbad, CA). All other reagents were obtained from Fisher Scientific (Tustin, CA).
Methods
PC-12 cells (ATCC, Manassas, VA) passages 6 through 9 were used. Cells were grown in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis MO) with 5 % fetal bovine serum and 10 % horse serum (ATCC, Manassas, VA), 1 % penicillin/streptomycin, and 25 mM glucose. Cells were incubated in 5 % carbon dioxide incubators at 37°C. At 75-80 % confluence, cells were subcultured onto poly-Llysine-coated dishes (BD, San Diego CA) and allowed to attach for 24 h. NGF (Alamones lab, Israel), 50 ng/mL, was then added and cells were allowed to differentiate. Approximately 75 % of media was replaced every 2-3 days until 60-70 % of the cells were differentiated, as determined by microscopy. Undifferentiated PC-12 cells exposed to NGF for 3 to 5 days exhibit neuronal phenotype such as responding to neurotransmitters [10] .
Treatment
Normal media was replaced with glucose-free, supplemented DMEM with either 0 or 10 U/mL EPO. Cells were then placed in a hypoxic chamber with less than 1 % oxygen for 2 h [1] . The media was then replaced with normal media and cells were allowed to recover for 18 h. Cells were then collected for cell assessment using cell death assay, western blotting, ROS assay, gelatin zymography, or reverse transcriptase polymerase chain reaction (RT-PCR).
Assessment of Reactive Oxygen Species Formation
ROS formation was assessed immediately after OGD with OxiSelect™ ROS Assay Kit (Cell Biolabs Inc., San Diego CA). The assay used 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) and was performed according to manufacturer's protocol. Briefly, cells were washed with Dulbecco's phosphate buffer saline (DPBS) and incubated with 1 mM of DCFH-DA in serum-free media for 1 h. Media was discarded and cells washed with DPBS to remove unabsorbed DCFH-DA. DCF was then evaluated by spectrophotometry at wavelength 480 nm excitation/530 nm emission wavelength in a 96-well plate reader (BioRad, Hercules CA). The levels of DCF in cells corresponded to the quantity of ROS formation.
Protein Extraction and Western Blotting
Cells were collected by centrifugation and lysed using radioimmunoprecipitation assay lysis buffer [20 mM Tris, pH 7.5, 150 mM NaCl, 1 % NP40, 0.5 % Na deoxycholate, 1 mM EDTA, and 0.1 % sodium dodecyl sulfate (SDS)] supplemented with mammalian protease inhibitor cocktail, phenylmethanesulfonyl fluoride (Sigma-Aldrich, St. Louis, MO) and sodium orthovanadate (Santa Cruz, Hercules CA). Prior to lysis, cells were rinsed with cold PBS. Cell lysis was enhanced by three rapid freeze-thaw cycles using liquid nitrogen. Lysed cells were centrifugated at 4°C for 10 min and the supernatant collected. The protein concentration was assessed using the Bradford assay (BioRad, Hercules, CA). SDS-PAGE electrophoresis was performed as previously described [11] .
Transfection
Prior to transfection, differentiated cells at a density of 2×10 Reverse Transcriptase Polymerase Chain Reaction RNA was extracted using TRIZOL reagent (Invitrogen). DNA was synthesized using SuperScript® First-Strand Synthesis System for RT-PCR (Invitrogen). PCR for HIF-1α, PHD-2, VHL, and internal standard GAPDH was performed using the following primers: (forward 5′GGCTTTGTTATGTGCTAAC3′ and reverse 5′ACTTGATGTTCATCGTCCTC3′ for HIF-1α), (forward 5′TAAACGGCCGAACGAAAGC3′ and reverse 5′ GGGTTATCAACGTGACGGACA3′ for PHD-2), (forward 5′ ACAGGATGTGCAAGGACAAGTG3′ and reverse 5′ TAGTCTGCAGCATTCCGTGAGT3′ for VHL), and (forward 5′ACCACAGTCCATGCCATCAC3′ and reverse 5′ TCCACCACCCTGTTGCTGTA3′ for GAPDH). Samples were cycled using a 2720 thermal cycler (Applied Biosciences). The samples were denatured at 95°C for 5 min followed by 35 cycles of amplification for HIF-1α, PHD-2, and VHL and 25 cycles for GAPDH. The amplification cycle consisted of 1 min denaturation at 94°C, 1 min annealing at 55°C, 1.5 min extension at 72°C, and a final extension of 5 min at 72°C. Samples were electrophoresed on 2 % agarose gel with 0.5 μg/mL ethidium bromide. Gels were visualized under UV light and photographed, and the optical densities of the bands were analyzed with Quantity One software (BioRad) [18] Cell Death Assessment Cell death was also evaluated by trypan exclusion as previously described [36] . The formula used to calculate the percentage of cell death was as follows: (Trypan blue positive cells)]/total cell counted)×100. The average of all six counts was used.
Gelatin Zymography
Briefly, 60 μg samples of protein extract was prepared and separated by electrophoresis in 10 % Tris-glycine gel with 0.1 % gelatin as substrate (Bio-Rad, Hercules, CA). The gel was re-natured for 1 h and then incubated with development buffer at 37°C for 48 h. After development, the gel was stained with 0.5 % Coomassie Brilliant Blue R-250 for 1 h and then distained for 18 to 24 h. MMP activity was visualized and photographed with a Versa Doc imager (BioRad, Hercules, CA) and the optical densities were calculated with Image J (version 1.0) software (NIH).
Statistical Analysis
All data are presented as mean±standard deviation. All data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey test. Data sets that failed the normality test were analyzed using Kruskal-Wallis ANOVA on Ranks. Sigma Stat software version 3.5 (DUNDAS software LTD. Germany) was used for all statistical evaluations.
Results

Determining if Both HIF-1α and HIF-2α Are Inhibited by EPO Treatment
To determine if the reduction in HIF-1α expression results in the upregulation of HIF-2α after EPO treatment (10 U/mL), we evaluated the expression of both HIF-1α and HIF-2α following OGD. HIF-1α expression was significantly lower (p <0.5) in EPO-treated groups, when compared to untreated (Fig. 1a, b) . However, HIF-2α expression remained unchanged in EPO-treated groups (Fig. 1c) , suggesting that HIF-1α, not HIF-2α, plays a key role in hypoxia during OGD. A significant increase (p <0.01) in PHD-2 expression was also observed in the EPO-treated group, when compared to normoxic and untreated groups. PHD-2 was the only PHD to play a critical role in HIF degradation; therefore, PHD-2 was the main focus of this study.
The Effect of EPO and PHD-2 Inhibition on ROS Formation and HIF-1α and PHD-2 Expression
The primary mediators of HIF-α expression are ROS and hypoxia. Therefore, we evaluated the effects of EPO treatment on ROS formation by adding a treated group with PHD-2 siRNA or an EPOR-Fc chimera (1 ng/mL). The siRNA or EPOR-Fc would competitively bind to the EPO receptor, diminishing the effects of the treatment. The optimal dose of EPOR-Fc chimera was determined experimentally, in its ability to inhibit JAK-2 phosphorylation in EPO-treated differentiated PC-12 cells (data not shown). The formation of ROS was increased in all groups following OGD, except groups treated with 10 U/mL EPO and control siRNA+EPO groups (Fig. 2c, f) . In accordance to an increase in ROS formation, HIF-1α expression was also shown to be upregulated. HIF-1α expression was increased in all of groups exhibiting high ROS (p <0.01), yet decreased in EPO-treated groups (Fig. 2a, d) . Conversely, PHD-2 expression was inversely correlated with ROS formation and HIF-1α expression. PHD-2 expression was notably increased in the 10 U/mL EPO-treated groups (p <0.01) compared to normoxia, untreated, EPOR-Fc chimera, and chimera with EPO (Fig. 2b) . This data suggests that EPO directly or indirectly alters ROS formation and HIF-1α and PHD-2 expression in differentiated PC-12 cells. In the presence of control siRNA and OGD, EPO treatment restored PHD-2 protein levels to 2/3 of the basal levels observed in normoxic cells (Fig. 2e) . All transfected groups, with or without EPO treatment, expressed high levels of ROS, when compared to normal groups. This data is not unusual, as transfected cells were exposed to low serum for approximately 24 h. Both low serum and exposure to Lipofectamine reagent negatively alters the mitochondrial dynamic, thereby promoting ROS formation. Cell death percentage was also higher in normoxia groups that had been transfected (Fig. 4e ), yet had not gone through the OGD. ROS assay has also seen an increase in ROS production in transfected normoxic groups (Fig. 2c) . Although the control siRNA with EPO treatment group showed an increase in PHD-2 expression and decrease in HIF-1α, PHD-2 siRNA with EPO treatment group increased in HIF-1α and showed no increase in PHD-2 expression ( Fig. 2d-f ). This suggests that EPO's target protein is inhibited, decreasing the treatments neuroprotective effects.
Determining the Effects of EPO Treatment on the mRNA Levels of HIF-1α, PHD-2, and VHL Changes in protein expression are not always indicative of transcriptional changes. Thus, RT-PCR was performed to determine if the changes observed in HIF-1α and PHD-2 expression with EPO treatment and inhibitor were at the transcription or translational level. Silencing of PHD-2, via siRNA, triggered a significant increase (p <0.01) in HIF-1α transcription when compared to 10 U/mL EPO-treated group. On the contrary, competitive inhibition of EPO did not affect HIF-1α transcription levels (Fig. 3a, d ). This suggests that EPO inhibition of HIF-1α is only on the protein level alluding Fig. 1 The profile of HIF-1α, HIF-2α, and PHD-2 following 2 h of OGD. a A representative image of a western blot of HIF-1α, HIF-2α, PHD-2, and the β-actin as the loading control. b Densiometric quantification of HIF-1α expression. c HIF-2α expression following EPO treatment. d PHD-2 expression following OGD. Data represent mean (±SD), n =6 in all groups. *p <0.01 compared to normoxia. δ p <0.01 compared to untreated. # p <0.01 compared to 10 U/mL EPO-treated group. One-way ANOVA was used for all analysis. HIF-1α, p ≤0.001 using KruskalWallis ANOVA on Ranks. PHD-2, p <0.001. HIF-1α but not HIF-2α expression was altered in the presence of EPO treatment Fig. 2 The effect of EPO treatment on ROS formation, HIF-1α and PHD-2 expression in the presence of EPO and PHD-2 inhibition. a HIF-1α protein expression in the presence and absence of EPOR chimera a competitive inhibitor of EPO. b Densiometric quantification of PHD-2 expression in the presence or absence of EPOR chimera. c ROS formation during OGD in the presence or absence of EPO inhibitor. d HIF-1α expression after OGD in the presence of PHD-2 siRNA. e PHD-2 expression after OGD in the presence of siRNAs. f ROS formation during OGD in the presence or absence of PHD-2 siRNA. Data represent the mean and (±SD), n =6 in all groups. *p <0.01 compared to normoxia. # p <0.01 compared to 10 U/mL EPO-treated group. &p <0.05 compared to normoxia+control siRNA. δ p <0.01 compared to PHD-2siRNA+ EPO. One-way ANOVA was used for all analysis. pH, p =0.015 using Kruskal-Wallis ANOVA on Ranks. HIF-1α, p ≤0.001, using KruskalWallis ANOVA on Ranks. PHD-2, p <0.001. Inhibition of EPO or PHD-2 enhanced HIF-1α expression and ROS formation Fig. 3 The effect of EPO treatment on mRNA levels of HIF-1α, PHD-2, and VHL in the presence of EPO and PHD-2 inhibition. a HIF-1α mRNA expression after OGD in the presence of EPOR chimera. b PHD-2 mRNA expression after OGD in the presence of EPOR chimera. c Densiometric quantification of VHL in presence of EPO inhibitor following OGD. d HIF-1α mRNA expression after OGD during EPO inhibition. e PHD-2 mRNA expression in the presence of PHD-2 siRNA following OGD. f VHL mRNA expression in presence PHD-2 siRNA following OGD. Data represent the mean and (±SD), n =6 in all groups. *p <0.01 compared to normoxia. # p <0.01 compared to 10 U/mL EPOtreated group. &p <0.05 compared to normoxia+control siRNA. δ p < 0.01 compared to PHD-2 siRNA+EPO. HIF-1α, p =< 0.001, p ≤0.001, using Kruskal-Wallis ANOVA on Ranks. PHD-2, p ≤0.001, using Kruskal-Wallis ANOVA on Ranks. VHL, p ≤0.001, using Kruskal-Wallis ANOVA on Ranks Inhibition of PHD-2 enhanced HIF-1α transcription in the presence and absence of EPO to possibly conformation change or indirect inhibition. Alternately, either inhibition of EPOR or silencing of PHD-2 significantly lowered mRNA levels of PHD-2 (Fig. 3b, e) . Downstream effecter of HIF-1α degradation, VHL, was significantly increased in EPO-treated group compared to normoxia and EPOR chimera with and without EPO. Additionally, VHL mRNA was significantly higher in siRNA+ EPO group compared to SiRNA control, normoxia, and PHD-2 siRNA+EPO (Fig. 3c, f) . Although VHL is significantly changed, this finding is inconclusive in the absence of detectable protein levels of VHL in the cells. This observation alludes to PHD-2 as one of the primary effecter of HIF-1α inhibition and subsequent neuroprotection in PC-12 cells.
Inhibition of EPO or PHD-2 Alters MMP-9 Activity and Reversed EPO's Neuroprotection MMP-9 downstream gene of HIF-1α is associated with exacerbated injury and cell death in the acute stages of hypoxiaischemia. Thus, MMP-9 activity and cell death were assessed to determine if EPO-induced HIF-1α inhibition affects the downstream gene expression and subsequent cell death. As expected, EPO treatment was associated with lower MMP-9 activity. Inhibition of PHD-2 rapidly reversed EPO-induced MMP-9 inhibition, resulting in significantly higher level of MMP-9 activity in PHD-2 siRNA+EPO group compared to 10 U/mL EPO and control siRNA+EPO (Fig. 4b-e ). Yet, EPOR-Fc chimera did not appear to negatively affect MMP-9 activity in the presence of EPO. Cell death was also found to be correlated with an increase in MMP-9 activity. Inhibition of EPO or PHD-2 with or without EPO visibly reversed EPOinduced neuroprotection compared to 10 U/mL (p <0.01) EPO (Fig. 4c, e) .
Discussion
Our findings showed that EPO-induced inhibition of HIF-1α was associated with elevated transcription and translation of PHD-2. Inhibition of EPO had prompted an increase in HIF-1α protein expression, yet mRNA levels were not affected. EPO treatment enhanced PHD-2 mRNA production and protein expression, reducing ROS formation, MMP-9 activity, and cell death.
HIF-1 and HIF-2α has 40 % homology. HIF-2α has been shown to bind to the beta subunit of HIF1α during hypoxia [24] . An accumulation of HIF-1α or HIF-2α during hypoxia is tissue-dependant. The specific HIF in neuronal tissue is uncertain and further investigation was needed [41] . However, this study evaluates both HIF-1α and HIF-2α, revealing that HIF-2α protein expression was relatively unchanged during OGD with or without EPO treatment in differentiated PC-12 cells. This indicated that HIF-1α, not HIF-2α, is primarily associated with hypoxia in differentiated PC-12 cells. HIF-1α was increased in cells undergoing OGD, but notably was decreased with EPO treatment. In the past, the attenuation of HIF-1α protein expression by the administration of exogenous EPO was not previously described, thus warranted further investigation. EPO is a downstream gene of HIF-1α [34] . It was speculated that the apparent EPO-induced inhibition of HIF-1α was the result of a negative feedback inhibition. However, the investigation of the primary regulators of HIF-1α degradation, PHD-2 and ROS, alluded to a much more complex mechanism.
The absence of oxygen and the presence of ROS promoted the destabilization of PHD-2 [7, 13, 14, 21] . HIF degradation pathways require either hydroxylation or acetylation, which is PHD-2-and oxygen-dependent. This interaction allows for the poly ubiquitination and proteasome-dependent degradation of HIF-1α.
There are three isoforms of HIF-PHDs (PHD1-3) hydroxylase involved in HIF hydroxylation in mammals. Previously, it was thought that all three PHDs were necessary for HIF ubiquitination and subsequent degradation. However, knockdown studies showed that only PHD-2 is critical for HIF-1α degradation under normoxic conditions [2, 4] and so PHD-2 was manipulated and evaluated in this study. PHDs are extremely sensitive to low O 2 concentration, making them ideal for oxygen sensing [13, 16] . They are dioxygenases that catalyze oxygen-dependent hydroxylation of HIF-1α prolyl residues and promotes the degradation of both HIF-1α and HIF-2α [8] . As expected, there is an inverse correlation between HIF-1α and PHD-2 protein expression after hypoxia ( Figs. 1 and 2 ) and an increase in ROS formation that upregulated with HIF-1α expression. Our data comes into agreement with past publication, which demonstrated that reduced oxygen or increased ROS allows for the stabilization and accumulation of HIF-1α [7, 14, 23, 29, 38] . Also, others findings have shown that low levels of oxygen or high levels of ROS promote the destabilization of PHD-2 [7, 13, 14, 21] .
Studies have shown that prolyl hydroxylation and acetylation control cellular HIF-1α levels by governing the physical interaction between HIF-1α and VHL. VHL binds with elongin B, elongin C, Rbx1, and Cul2 to form an E3 ubiquitin ligase. E3 ubiquitin ligase is unable to bind to HIF-1α during hypoxia because HIF-1α lacks hydroxylation or acetylation [19, 20] . Thus, it was expected that EPO-induced inhibition of HIF-1α would increase the expression of regulatory proteins, PHD and pVHL, and would not affect transcriptional levels. Yet, due to a low protein expression of pVHL, expression could not be quantified (data not shown). As expected, HIF-1α protein levels were significantly reduced by EPO treatment and did not affect mRNA levels. This suggests that EPOinduced inhibition of HIF-α has no direct effect on HIF-1α transcription, meaning that changes in HIF-1α protein expression were possibly mediated by either physical interaction of Fig. 4 The effects of EPO treatment on MMP-9 activity and subsequent cell death after OGD. a Shows representative image of NGF-differentiated cells with and without EPO and OGD. b, d Densiometric quantification of MMP-9 activity b in the presence of EPOR chimera; d in the presence of PHD-2 siRNA. c, e Percent cell death as assess by trypan blue exclusion c in the presence of EPOR chimera; e in the presence of PHD-2 siRNA. Data represent the mean and (±SD), n =6 in all groups. *p <0.01 compared to normoxia. #p <0.01 compared to 10 U/mL EPO-treated group. &p <0.05 compared to normoxia+control siRNA. δ p <0.01 compared to PHD-2siRNA+EPO. MMP-9, p =0.001; cell death, p ≤0.001, using Kruskal-Wallis ANOVA on Ranks. Inhibition of PHD-2 significantly increased MMP-9 activity and cell death with and without EPO EPO with HIF-1α or through transcriptional regulation of a HIF-1α regulator (Fig. 2) . The threefold increase in HIF-1a observed in the presence of EPOR chimera was unexpected, yet not surprising. Since EPO is a downstream gene of HIF that is endogenously synthesized during hypoxia, it is plausible that the circulating EPOR were acting as a positive feedback loop for HIF-1α protein, possibly signaling that EPO levels are low. It was no surprise that EPO treatment propagated an increase in both transcriptional and translational levels of PHD-2. This alluded to the modulation of PHD-2 levels as one of the primary mechanism by which exogenous EPO inhibits HIF-1α and confers neuroprotection in NGF differentiated PC-12 cells during oxygen and glucose deprivation. Conversely, Ratan and colleagues showed that inhibition of PHD and activation HIF-1α was associated with neuroprotection in vivo and in vitro [26, 32, 35] . The apparent contradiction in these reports attests to the biphasic nature of HIF-1α, which could be both beneficial as well as detrimental [6, 15, 27] . Baranova and colleagues who described an oscillation of HIF-1 levels following hypoxia-ischemia best explain the dichotomy of HIF-1 neuroprotection. Additionally, it was proposed that transient increases in HIF-1α within the first 24 h after an injury was associated with elevation of proapoptotic genes; however, downstream prosurvival genes of HIF-1α were later (>24 h) unregulated with sustained elevation of HIF-1α [3] . Thus, HIF-1α is detrimental in the acute stages of injury but beneficial in the delayed/recovery stage of injury.
Given that the direct or indirect interaction of EPO with HIF-1α is biphasic and its primary regulator PHD-2, caution should be exercised when using EPO in stroke therapy. The time/duration of EPO exposure/treatment is the key to harness the beneficial neuroprotective effects of EPO, without triggering the detrimental effect of delayed/prolonged inhibition of HIF-1α. Silencing of PHD-2 prompted a notable increase in both protein and mRNA levels of HIF-1α, MMP-9 activity, and the resultant cell death even in the presence of EPO treatment. These observations lends to the conclusion that PHD-2 is one of the key mediator of EPO-induced neuroprotection in NGF differentiated PC-12 cells.
